Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Current insights in obstetric antiphospholipid syndrome

Research output: Contribution to journalReviewResearchpeer-review

  1. Diving into the oocyte pool

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Imprinting disorders after assisted reproductive technologies

    Research output: Contribution to journalJournal articleResearch

  1. Functional neuroimaging of recovery from motor conversion disorder: A case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical utility of anti-MOG antibody testing in a Danish cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE OF REVIEW: Antiphospholipid syndrome (APS) is defined as the association of thrombotic events and/or obstetric morbidity in patients persistently positive for antiphospholipid antibodies (aPL). In this review, we will highlight the most important clinical presentations of APS with a focus on the obstetric morbidity, the current management strategies and the outlook for the future.

RECENT FINDINGS: The use of aspirin and heparin has improved the pregnancy outcome in obstetric APS and approximately 70% of pregnant women with APS have a successful pregnancy outcome. Unfortunately, the current standard of care does not prevent all pregnancy complications as the current treatment fails in 20-30% of APS pregnancies. This therefore highlights the need for alternative treatments to improve obstetrical outcome. Other treatment options are currently explored and retrospective studies show that pravastatin for example is beneficial in women with aPL-related early preeclampsia. Moreover, the immunmodulator hydroxychloroquine may play a beneficial role in the prevention of aPL-related pregnancy complications.

SUMMARY: APS is among the most frequent acquired risk factors for a treatable cause of recurrent pregnancy loss and increases the risk of conditions associated with ischaemic placental dysfunction, such as fetal growth restriction, preeclampsia, premature birth and intrauterine death. Current treatment is mainly based on aspirin and heparin. Studies to inform on alternative treatment options are urgently needed.

Original languageEnglish
JournalCurrent Opinion in Obstetrics and Gynecology
Volume29
Issue number6
Pages (from-to)397-403
Number of pages7
ISSN1040-872X
DOIs
Publication statusPublished - Dec 2017

    Research areas

  • Journal Article

ID: 52386311